Devices Incorporating Tissues or Cells of Animal or Human Origin, or Their Derivatives: Data Expectations Under EU MDR
Shirantha Samarappuli, PhD
20 Jun, 2025
āI want to thank your team for the valuable contribution and partnership during this project. Itās noteworthy to mention that the clinical assessment phase was passed the BSI assessment without any questions / additional information being asked. This is primarily the CER/CEP evaluation and risk assessment.
Thank you the entire Celegence Team for the timely delivery of quality work which is continue to be accepted by EU Notified Bodies.ā
Other Related Articles
07 May, 2026
29 Apr, 2026
22 Apr, 2026
10 Apr, 2026
